Signet Accel’s Avec™ ensures analytics and data visualization tools have access to all data possible. “It can aggregate multiple disparate databases all over the world—as it is, and where it is—into a pristine data stream, eliminating the need for duplicitous capital expenditures,” remarks Raden. “And our advanced query functionality allows healthcare professionals to ask more questions and receive more complete answers, targeting therapies faster and with greater precision.” Initiated at The Ohio State University in collaboration with investigators and technologists on an international scale, Avec eschews traditional data sharing and takes a harmonization approach to truly connect data, allowing stakeholders—including patients, providers, payers, researchers, and investors—to make decisions that can usher in innovation.
At Signet Accel, we bring true interoperability to healthcare—profoundly affecting the ability of investigators and clinicians to understand, treat, and cure, significantly reducing the time it takes to see real results
“At Signet Accel, we bring true interoperability to healthcare— profoundly affecting the ability of investigators and clinicians to understand, treat, and cure, siginificantly reducing the time it takes to see real results,” delineates Raden. Signet Accel and the 18-site international Hairy Cell Leukemia Research Foundation (HCL-RF) are collaborating to bring interoperability to the fight against Hairy Cell Leukemia (HCL), a rare form of chronic adult leukemia. In usual medical practices, the availability of data related to rare diseases is often limited, because organizational and policy barriers often preclude the use of centralized repositories, particularly when it is requisite to engage a geographically diverse group of sites. With Avec, data is exchanged and rendered via encrypted channels—allowing practitioners to accelerate critical research with improved therapies and treatment options for patients diagnosed with rare diseases.
With a strong business model in place, the future of Signet Accel looks favorable in the coming years, with added associates and continued expansion. “Through our organic growth and strategic acquisitions, we will continue to deliver true interoperability for advancing academic research, achieving meaningful use objectives, and enabling the continuum of care,” concludes Raden.